Replimune Group Inc (REPL NASDAQ) stock market data APIs
$4.8869
0.21(4.3%)
as of May 14, 2026
Try our APIs with
free plan!
Replimune Group Inc Financial Data Overview
Price chart is built with
Anychart
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Prev. Close
4.8869
Open
5.0993
High
5.5469
Low
4.5446
52 wk Range
1.5-13.24
Market Cap
407 M
Shares Outstanding
82 573 K
EPS
0
Beta
0.116
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Replimune Group Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Replimune Group Inc data using free add-ons & libraries
Get Replimune Group Inc Fundamental Data
Replimune Group Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -318 880 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-14
- EPS/Forecast: -0.7272
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Replimune Group Inc News
New
Replimune surges day after FDA Commissioner Makary resigns
[Business graph, chart green background.Copy space] design master * Replimune (REPL [https://seekingalpha.com/symbol/REPL]), which has been critical of the FDA over its application for a melanoma t...
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Quantum Cyber (NASDAQ:QUCY) shares rose 163.0% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million. Whitehawk Therapeutics (NASDAQ:WHW...
Oncolytics Biotech Reports Data in Colorectal Cancer Study
By Karen Roman Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to the ...
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech stocks to invest in. TheFly reported on April 13 that Jefferies cut its rat...
Get Replimune Group Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
